Navigation Links
VetNostic Laboratories® Announces New Testing for Dog Breeds
Date:10/27/2011

HAMILTON, N.J., Oct. 27, 2011 /PRNewswire/ -- VetNostic Laboratories® offers state-of-the-art genetic testing services for dog breeders and owners. Using DNA analysis, they are able to accurately and specifically determine whether or not a dog carries disease-causing genes. Providing reliable identification of these "carriers" ensures healthy litters and a successful breeding program. At this time, VetNostic Laboratories® is pleased to introduce two new tests to its growing diagnostic menu, Primary Lens Luxation and Greyhound Polyneuropathy.

Primary Lens Luxation (PLL) is a potentially blinding inherited disease in many Terrier breeds. It occurs when the ligaments holding the lens of the eye break down, causing it to dislocate. This can result in painful, teary, red eyes that may look hazy or cloudy. If not diagnosed and properly treated, PLL may lead to Uveitis and/or Glaucoma. This test is relevant to the following breeds: American Eskimo Dog, American Hairless (Rat) Terrier, Australian Cattle Dog, Chinese Crested, Chinese Foo Dog, Jack Russell Terrier, Jagd Terrier, Lakeland Terrier, Lancashire Heeler, Miniature Bull Terrier, Parson Russell Terrier, Rat Terrier, Russell Terrier, Sealyham Terrier, Teddy Roosevelt Terrier, Tenterfield Terrier, Tibetan Terrier, Toy Fox Terrier, Volpino Italiano, and Welsh Terrier.

Greyhound Polyneuropathy is a fatal neurological disease specific to the Greyhound show dog population. Symptoms include decreased or absent reflexes, muscle weakness, muscle pain and cramps, and a bunny-hopping gait. It usually appears within the first 9 months of age and then progresses so quickly that most affected dogs must be euthanized within their first year of life. Currently, there is no effective treatment for Greyhound Polyneuropathy.

VetNostic Laboratories® genetic tests for PLL and Greyhound Polyneuropathy can reliably identify dogs that are either clear, or possess one or two copies of the disease-causing genes which they may pass to their offspring. This clear, carrier, or affected result can help breeders determine which animals to include in their breeding programs.

Dr. Martin E. Adelson, Vice President of the Genesis Biotechology Group, stated, "We are pleased to continually add to the diversity of testing services offered by VetNostic Laboratories®. These most recent tests will help breeders to eliminate diseases such as PLL and Greyhound Polyneuropathy from future generations. This testing also provides true value to breeders as they can authenticate that their puppies are clear of common disorders caused by genetic mutations. It's an exciting time in the field of canine molecular diagnostics."

VetNostic Laboratories®, a division of Medical Diagnostic Laboratories, L.L.C., is a company within the Genesis Biotechnology Group. They are located in "Einstein's Alley," the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible in the New York, New Jersey, and Pennsylvania area.

VetNostic Laboratories® offers a web-based shopping cart to make molecular diagnostic testing readily available to the dog breeder and owner communities. Through this online ordering system, they are able to view test descriptions and order specimen collections kits. Specimen collection instructions and a "How-To" video facilitate step-by-step collection of cheek swabs from dogs.

To find out more, please visit http://www.vetnostic.com

Contact:

Rob Mason
Research Scientist
rmason@vetnostic.com
877.255.9208
http://www.vetnostic.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE VetNostic Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):